# The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 8

Extent: E+W+S+N.I.

In regulation 13 (new regulation B17 and C17 (good manufacturing practice and good distribution practice))—
(a) in the inserted regulation B17—
(i) in paragraph (1)—
(aa) for “Ministers” substitute “ Secretary of State ”;
(bb) after “by regulations” insert “ in respect of Great Britain ”;
(ii) in paragraph (2)(b) after “UK marketing authorisation” insert “ or EU marketing authorisation ”;
(iii) in paragraph (3)—
(aa) after “have effect” insert “ in Great Britain ”;
(bb) for “exit day” in both places it occurs substitute “ IP completion day ”;
(iv) in paragraph (4)—
(aa) for “Ministers” substitute “ Secretary of State ”;
(bb) after “by regulations” insert “ in respect of Great Britain ”;
(b) in the inserted regulation C17—
(i) in paragraph (1), after “may publish” insert “ in relation to the manufacture or assembly of a medicinal product in, or import to, Great Britain ”;
(ii) in paragraph (3) for “exit day” in both places it occurs substitute “ IP completion day ”.

---
Source: https://www.legislation.gov.uk/uksi/2020/1488/schedule/2/paragraph/8 (the official version)
Page: https://openlegislation.uk/human-medicines-amendment-etc-eu-exit-regulations-2020/schedule-2/paragraph-8
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.